| Name | Title | Contact Details |
|---|
Central Wyoming Counseling Center is a non-profit Community Mental Health and Substance Abuse Treatment Center that is dedicated to helping Residents of Wyoming.
Diaceutics believe that every patient should get the treatment they deserve. We have worked on every Precision Medicine brought to market and we are trusted by the worlds leading pharmaceutical companies. Find out about DXRX - the Diagnostic Network f...
Ridgeview’s earliest beginnings date back to 1954 when at the suggestion of the Oak Ridge schools’ Pupil Personnel Department, under the leadership of Ms.Sarah Ketron, a group of Oak Ridge and Anderson County citizens met to consider forming a mental h...
Rafael Holdings is focused on the development of novel cancer therapies. The company is a significant investor in two clinical stage oncology companies, Rafael Pharmaceuticals, Inc., and LipoMedix Pharmaceuticals Ltd. Through its wholly owned Barer Institute subsidiary, the company is developing a pipeline of compounds focused on the regulation of cancer metabolism.
ORIC was established in 2014 with a bold vision of Overcoming Resistance in Cancer. Resistance limits the efficacy of otherwise significant cancer treatment breakthroughs, regardless of modality. Our ambition at ORIC is to discover and develop innovative therapies that benefit patients with cancer, including by making existing therapies more effective for a longer period of time. Our initial project was a small molecule antagonist of the glucocorticoid receptor (GR), which has been implicated in resistance to various treatment modalities—including chemotherapy, immunotherapy, and anti-hormonal therapy—and across multiple cancers. The resulting product candidate, ORIC-101, is now being studied in clinical trials for a range of solid tumors. ORIC-101 and other pipeline programs are a result of rigorous, hands-on experimentation and medicinal chemistry efforts led by our internal team of scientists in biology, medicinal chemistry, DMPK and translational medicine, with assistance from academic collaborators and continued guidance from our founders and board members. This collective team maintains an unwavering focus on improving the lives of patients by tackling the problem of cancer treatment resistance.